Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection

Background: Antibiotics alone are often insufficient to treat recurrent C. difficile infection (rCDI) because they have no activity against C. difficile spores that germinate within a disrupted microbiome. SER-109, an investigational, oral, microbiome therapeutic comprised of purified Firmicutes spo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, Matthew, Silverman, Michael, Louie, Thomas, Wang, Elaine, Kraft, Colleen, Ramesh, Mayur, Bogdanovich, Tatiana, Brady, Kelly, Lombardi, David, Memisoglu, Asli, De, Ananya, Hasson, Brooke, Lee, Christine, Feuerstadt, Paul, Pardi, Darrell, Kelly, Colleen, Daley, Peter, Oguchi, Godson, McGovern, Barbara, Moltke, Lisa Von
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
C. difficile
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594104/
http://dx.doi.org/10.1017/ash.2023.214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594104/
http://dx.doi.org/10.1017/ash.2023.214

Ejemplares similares